Sutro Biopharma Inc. has announced the dosing of the first cohort of patients in its Phase 1 clinical trial evaluating STRO-004, a next-generation tissue factor (TF)-targeting antibody drug conjugate $(ADC)$, in patients with advanced TF-expressing solid tumors. The open-label, multicenter trial will assess the safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-004 in various cancer types, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and bladder cancer. Initial clinical data from the study are expected to be presented in mid-2026.